1
Depression
2
Patient
3
Science
4
Pipeline
5
About
Get In Touch
Get Involved

Are you looking to get involved with Aingeal? Simply get in touch through the form below and a team member will get back to you.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

The journey to a Better tomorrow

today
We have developed a new class of peptide- mimicking drugs to enhance the activity of an endogenous neurotrophic factor called BDNF (Brain-Derived Neurotrophic Factor). Increasing BDNF activity has shown therapeutic benefits for not only depression, but an array of brain disorders.

At Aingeal, our focus is on developing therapeutics for Treatment-Resistant Depression, Angelman Syndrome, and Traumatic Brain Injury.

our pipeline

Product Candidate
CN2097
Research
Preclinical
stAGE 1-3
Regulatory Review
Post Approval
Treatment Resistant Depression
Explain this step in detail.
Explain this step in detail.
Explain this step in detail.
Explain this step in detail.
Explain this step in detail.
Overview
CN2097 produces rapid antidepressant effects that we predict will benefit conventional treatment-resistant depression patients.
Target/Technology
BDNF regulation - TrkB, mTOR, and 5-HT2A
How It Works
Angelman Syndrome
Explain this step in detail.
Explain this step in detail.
Explain this step in detail.
Explain this step in detail.
Explain this step in detail.
Overview
CN2097 produces rapid antidepressant effects that we predict will benefit conventional treatment-resistant depression patients.
Target/Technology
BDNF regulation - TrkB, mTOR, and 5-HT2A
How It Works
Traumatic Brain Injury
Explain this step in detail.
Explain this step in detail.
Explain this step in detail.
Explain this step in detail.
Explain this step in detail.
Overview
CN2097 produces rapid antidepressant effects that we predict will benefit conventional treatment-resistant depression patients.
Target/Technology
BDNF regulation - TrkB, mTOR, and 5-HT2A
How It Works
Product Candidate
CN2097
Treatment Resistant Depression
Research
Preclinical
phase 1
phase 2
phase 3
CN2097 produces rapid antidepressant effects that we predict will benefit conventional treatment-resistant depression patients.
CN2097
Angelman Syndrome
Research
Preclinical
phase 1
phase 2
phase 3
CN2097 produces rapid antidepressant effects that we predict will benefit conventional treatment-resistant depression patients.
CN2097
Traumatic Brain Injury
Research
Preclinical
phase 1
phase 2
phase 3
CN2097 produces rapid antidepressant effects that we predict will benefit conventional treatment-resistant depression patients.
Get Involved
Product Candidate
Syn3
Research
Preclinical
stage 1-3
regulatory review
post approval
Treatment Resistant Depression
Explain this step in detail.
Explain this step in detail.
Explain this step in detail.
Explain this step in detail.
Explain this step in detail.
Overview
CN2097 produces rapid antidepressant effects that we predict will benefit conventional treatment-resistant depression patients.
Target/Technology
BDNF regulation - TrkB, mTOR, and 5-HT2A
How It Works
Angelman syndrome
Explain this step in detail.
Explain this step in detail.
Explain this step in detail.
Explain this step in detail.
Explain this step in detail.
Overview
CN2097 produces rapid antidepressant effects that we predict will benefit conventional treatment-resistant depression patients.
Target/Technology
BDNF regulation - TrkB, mTOR, and 5-HT2A
How It Works
Traumatic Brain Injury
Explain this step in detail.
Explain this step in detail.
Explain this step in detail.
Explain this step in detail.
Explain this step in detail.
Overview
CN2097 produces rapid antidepressant effects that we predict will benefit conventional treatment-resistant depression patients.
Target/Technology
BDNF regulation - TrkB, mTOR, and 5-HT2A
How It Works
Product Candidate
Syn3
Treatment Resistant Depression
Research
Preclinical
phase 1
phase 2
phase 3
CN2097 produces rapid antidepressant effects that we predict will benefit conventional treatment-resistant depression patients.
Syn3
Angelman Syndrome
Research
Preclinical
phase 1
phase 2
phase 3
CN2097 produces rapid antidepressant effects that we predict will benefit conventional treatment-resistant depression patients.
Syn3
Traumatic Brain Injury
Research
Preclinical
phase 1
phase 2
phase 3
CN2097 produces rapid antidepressant effects that we predict will benefit conventional treatment-resistant depression patients.
Get Involved
01
Depression
02
Patient
03
Science
04
Pipeline
05
About
Get Involved

Are you looking to get involved with Aingeal? Simply get in touch through the form below and a team member will get back to you

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.